Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold
Fintel reports that on October 1, 2026, Argus Research upgraded their outlook for Regeneron Pharmaceuticals (NASDAQGS:REGN) (BIT:1REGN) from Hold to Buy.Regeneron Pharmaceuticals, Inc. is an American biotechnology company primarily…